Cargando…
Bivalent non-human gal-α1-3-gal glycan epitopes in the Fc region of a monoclonal antibody model can be recognized by anti-Gal-α1-3-Gal IgE antibodies
Monoclonal antibody (mAb) production using non-human cells can introduce non-human glycan epitopes including terminal galactosyl-α1–3-galactose (α1–3-Gal) moieties. Cetuximab is a commercial mAb associated with causing anaphylaxis in some patients due to the binding of endogenous anti-α1–3-Gal IgE t...
Autores principales: | Hatfield, Grayson, Tepliakova, Lioudmila, Tran, Jessica, Lu, Huixin, Gilbert, Michel, Tam, Roger Y. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10376915/ https://www.ncbi.nlm.nih.gov/pubmed/37497986 http://dx.doi.org/10.1080/19420862.2023.2239405 |
Ejemplares similares
-
Biosynthesis of α-Gal Epitopes (Galα1-3Galβ1-4GlcNAc-R) and Their Unique Potential in Future α-Gal Therapies
por: Galili, Uri
Publicado: (2021) -
Characteristics of α-Gal epitope, anti-Gal antibody, α1,3 galactosyltransferase and its clinical exploitation (Review)
por: HUAI, GUOLI, et al.
Publicado: (2016) -
IgE, α-Gal and atherosclerosis
por: Wilson, Jeffrey M., et al.
Publicado: (2019) -
Conversion of Tumors into Autologous Vaccines by Intratumoral Injection of α-Gal Glycolipids that Induce Anti-Gal/α-Gal Epitope Interaction
por: Galili, Uri
Publicado: (2011) -
Course of IgE to α‐Gal in a Swedish population of α‐Gal syndrome patients
por: Apostolovic, Danijela, et al.
Publicado: (2021)